MS Injectable Agents



Patient Information				
nationt		male _{female} DOB: SS#:		
patient:		female DOB: 55#:		
address:		city state	zip	
primary phone number:		-		cell
caregiver:		allergies:		NKDA
		neight: weight: kg da		
	· · · · · ·			
Clincal Information				
	35 Secondary ICD-	10 Code: Date of first demyelination ng-remitting Secondary-progressive Primary-progre	ting event: ssive Progressive-relapsing	
	-	agent (if not preferred formulary agent):	ssive Progressive-relapsing	
Prior therapies	1 0	Reason for discontinuation		
Prescription	strength	directions	quantity	refill
Avonex [®] PFS	30 mcg	Titration dosing (Available only for SDV or for PFS	1 kit = 4 devices	0
Avonex [®] SDV		using AVOSTARTGRIP [™] Titration Kit) Week1: Inject 7.5 mcg (0.25 mL) IM once weekly; WEEK 2:		
Avonex [®] Pen		Inject 15 mcg (0.5 mL) IM once weekly; WEEK 3: Inject 22.5 mcg (0.75 mL) IM once weekly; WEEK		
Avonex [®] Pen		4+ Inject 30 mcg (1 ml.) IM once weekly		
		Inject 30 mcg IM once weekly	1 kit = 4 devices	1
Betaseron®	0.3 mg	Titration dose per package insert: WEEKS 1-2:	1 kit = 14 vials Betaseron [®]	0
Extavia®		0.0625 mg/0.25 mL Sub-Q every other day; WEEKS 3-4: 0.125 mg/0.5 mL Sub-Q every other		
		day; WEEKS 5-6: 0.1875 mg/0.75 mL Sub-Q		
		every other day; WEEK 7+: 0.25 mg/1 mL Sub-Q every other day		
		0.25 mg/1 mL Sub-Q every other day	1 kit=15 vials Extavia®	1
Copaxone [®] PFS	20 mg	Inject 20 mg Sub-Q daily	30 PFS	1
	40 mg	Inject 40 mg Sub-Q three times weekly	12 PFS	1
Glatopa [™] PFS	20 mg	Inject 20 mg Sub-Q once daily	30 PFS	
Lemtrada [™]	To order Lemtrada™, ple	ease see the Genzyme form at lemtradarems.com/Docs/Pdf/le	emtrada_rems_prescription_ordering_fo	rm.pdf
Plegridy™ Starter PFS Plegridy™ Starter PEN	125 mcg	Inject 63 mcg Sub-Q on day 1, 94 mcg on day 15, then 125 mcg every 14 days thereafter	1 kit = one 63 mcg + one 94 mcg device	0
Plegridy [™] PFS		Inject 125 mcg Sub-Q once every 14 days	1 kit = two 125 mcg devices	
Plegridy™ PEN				<u> </u>
Rebif [®] PFS Titration Pack	Titration to 22 MCG PFS only dose: Weeks 1-2: inject 4.4 mcg Sub-Q three times weekly; Weeks 3-4: Inject 11 mcg Sub-Q three times weekly; week 5 and thereafter: Inject 22 mcg Sub-Q three times weekly		6 x 8.8 mcg PFS and 6 x 22 mcg PFS	
Rebif [®] Rebidose Titration Pack		CG PFS only dose: Weeks 1-2: inject 8.8 mcg Sub-Q	6 x 8.8 mcg PFS and	1
	three times weekly; Weeks 3-4: Inject 22 mcg Sub-Q three times weekly; week 5 and thereafter: Inject 44 mcg Sub-Q three times weekly		6 x 22 mcg PFS 6 x 8.8 mcg Autoinjectors and	
		· · · · · · · · · · · · · · · · · · ·	6 x 22 mcg Autoinjectors	
Rebif [®] PFS	22 mcg/0.5 mL	Inject 22 mcg Sub-Q three times weekly Other:	12 x 22 mcg PFS 12 x 22 mcg Autoinjectors	
Rebif [®] Rebidose	44 mcg/0.5 mL	Inject 44 mcg Sub-Q three times weekly Other:	12 x 44 mcg PFS 12 x 44 mcg Autoinjectors	
Prescriber + Shipping I	nformation			
prescriber (print):	njormation	office	e contact:	
preferred method of conta	ct: phone fax	email preferred contact persons email:		
ship to: patient office	e alternate shipping addre	ss: street	city state	zip
office address: (street, suite, cit	y, state, zip)			
		NPI:	DEA:	
prescriber's signature:			date:	
I authorize Thrifty White Specialty Pharmacy can revoke this designation at any time by pro	and its representatives to act as an agent widing written notice to Thrifty White Sp	to initiate and execute the insurance prior authorization process for this prescription and any fut ecialty Pharmacy.	ure fills of the same prescription for the patient listed above. I	understand that
Insurance Information	please fax copy of	insurance card (front + back)		
Confidentiality Statement: This message is inte	ended only for the individual or entity to whi	ch it is addressed. It may contain information which may be proprietary and confidential. It may also con	tain privileged, confidential information which is exempt from discl	osure under

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is easempt from disclosure under applicable laws, including the Health. Insurance Portability Act (HTPAA). If you are not the intended recipient, please note that you are strictly prohibited from disclosure under the intended recipient, please note that you are strictly prohibited from disconstructions as to the proper destruction of the transmitted material. Thank you.